Literature DB >> 15381589

American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy.

Scott Schraff1, Craig S Derkay, Bonnie Burke, Louise Lawson.   

Abstract

OBJECTIVE: To evaluate how evolving treatment technologies have affected our management of recurrent respiratory papilloma (RRP) since the last comprehensive survey of pediatric otolaryngologists in 1998.
DESIGN: Web-based survey of all American Society of Pediatric Otolaryngology members residing in the United States, Canada, Europe, and Australia.
RESULTS: Evaluable survey results were tabulated from 74 practitioners in 62 separate practices managing 700 current children with RRP. A total of 150 (21%) of these patients presently receive adjuvant medical therapies with cidofovir and interferon, accounting for more than two thirds of the total. Sixty-one percent of patients treated with cidofovir have experienced a beneficial response. Distal spread of RRP has occurred in 94 (13%) of the 700 patients. Half of the practices surveyed have experienced a death from RRP, with 89% of deaths directly related to RRP. The laryngeal microdebrider (53%) has supplanted the carbon dioxide laser (42%) as the preferred means of surgically removing papilloma from the larynx in children. Spontaneous, apneic, and jet ventilation (88%) anesthesia techniques have replaced the use of laser-safe endotracheal tubes (10%) as the preferred anesthetic management. Routine human papillomavirus subtyping is practiced by 45% of respondents while 15% treat all their patients with antireflux medications. Half of respondents send lesions for histologic examination only if there is a change in growth pattern while one third send lesions with every surgery.
CONCLUSIONS: Recurrent respiratory papilloma continues to be a frustrating disease to treat and is associated with significant morbidity and mortality. There has been an evolution in the past decade toward the increased use of antiviral adjuvant therapy and the use of microdebrider techniques for surgical management.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381589     DOI: 10.1001/archotol.130.9.1039

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  27 in total

1.  Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir--a prospective study.

Authors:  Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

Review 2.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

3.  Infectivity of murine papillomavirus in the surgical byproducts of treated tail warts.

Authors:  Simon R Best; Daniel Esquivel; Rebecca Mellinger-Pilgrim; Richard B S Roden; Michael J Pitman
Journal:  Laryngoscope       Date:  2019-05-01       Impact factor: 3.325

Review 4.  [Current therapeutic options for recurrent respiratory papillomatosis].

Authors:  K Huber; H Sadick; K Götte
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

Review 5.  Adjuvant antiviral therapy for recurrent respiratory papillomatosis.

Authors:  Neil K Chadha; Adrian James
Journal:  Cochrane Database Syst Rev       Date:  2012-12-12

6.  Characterization of human papillomavirus type 11-specific immune responses in a preclinical model.

Authors:  Shiwen Peng; Simon R Best; Chien-Fu Hung; Myriam Loyo; Sofia Lyford-Pike; Paul W Flint; David E Tunkel; John R Saunders; T C Wu; Sara I Pai
Journal:  Laryngoscope       Date:  2010-03       Impact factor: 3.325

7.  Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis.

Authors:  M Graupp; M Gugatschka; K Kiesler; E Reckenzaun; G Hammer; G Friedrich
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-16       Impact factor: 2.503

8.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

Review 9.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 10.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.